MaxCyte Inc

MXCT remains in Stage 4 – Decline after the mid-July support breakdown confirmed sustained bearish control. Price trades below the 9/21/50 EMAs and the declining 200 DMA on elevated down-volume, and the Support Failure pattern suggests accelerating downside with the broken support acting as resistance. The asset is extremely oversold, so execution for the bearish medium-term thesis is best deferred. We will trim into strength, targeting rallies into the broken support zone and moving averages for entry.

• ↑Multi-platform Genentech license enhances recurring revenue streams
• ↑YoY net loss improvement from $12.4M to $8.9M reflects cost discipline
• ↓Q2 core revenue fell 15% to $6.5M; gross margin slipped to 77% from 82%